A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus

JAMA

Volumn 279, Issue 2, 1998, Pages 137-143

  Burge, Mark R ^a,b   Schmitz Fiorentino, Kristen ^a   Fischette, Christine ^b   Qualls, Clifford R ^c   Schade, David S ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; C PEPTIDE; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; INSULIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ADRENALIN RELEASE; ADULT; AGED; AGING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0032515368     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.2.137     Document Type: Article

References (28)

1. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-1241.
2. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 1989;12: 203-208.
3. Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin. 1989; 18:163-183.
4. Clinical practice recommendations of the American Diabetes Association. Diabetes Care. 1997;20 (suppl 1):S59.
5. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
6. Boden G, Soriano M, Hoeldke RD, Owen OE. Counterregulatory hormone release and glucose recovery after hypoglycemia in non-insulin-dependent diabetic patients. Diabetes. 1983;32:1055-1059.
7. Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-754.
8. Glipizide GITS. In: Physician's Desk Reference. Montvale, NJ: Medical Economics Press; 1996.
9. Nakagawa S, Nakayama H, Sasaki T, et al. A simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes. 1973;22:590-600.
10. Ensinck JW. Immunoassays for glucagon. In: Glucagon: Handbook of Experimental Pharmacology. New York, NY: Verlag; 1983;66.
11. Shah SD, Clutter WE, Cryer PE. External and internal standards in the single isotope derivative (radioenzymatic) assay of plasma norepinephrine and epinephrine in normal humans and persons with diabetes mellitus or chronic renal failure. J Lab Clin Med. 1985;106:624-629.
12. Rydberg T, Wahlin-Boll E, Melander A. Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography. J Chromatogr. 1991;564:223-233.
13. Wahlin-Boll E, Melander A. High performance liquid chromatographic determination of glipizide and some other sulfonylurea drugs in serum. J Chromatogr. 1979;164:541-546.
14. Clutter WE, Bier DM, Shah SD, Cryer PE. Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest. 1980;66:94-101.
15. SAS/STAT User's Guide Volume 2, Version 6. Cary, NC: SAS Institute Inc; 1990:1135-1194.
16. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes. 1987;36:523-534.
17. Siegel JS. Recent and prospective trends for the elderly population and some implications for health care. In: Haynes S, Feinleib M, eds. Second Conference on the Epidemiology of Aging. Washington, DC: US Government Printing Office; 1980. DHHS NIH publication 80-969.
18. Asplund K, Wilholm B-E, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia. 1983;24:412-417.
19. Popp DA, Shah SD, Cryer PE. The role of epinephrine mediated β-adrenergic mechanisms in hypoglycemic glucose counterregulation and post-hypoglycemic hyperglycemia in insulin-independent diabetes mellitus. J Clin Invest. 1982;69:315-326.
20. Mokan M, Mitrakou A, Veneman T, et al. Hypoglycemic awareness in IDDM. Diabetes Care. 1994;17:1397-1403.
21. Garber AJ, Cryer PE, Santiago JV, Haymond MW, Pagliara AS, Kipnis DM. The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest. 1976;58:7-15.
22. Mitrakou T, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991;260:E67-E74.
23. Borg WP, During MJ, Sherwin RS, Borg MA, Brines ML, Schulman GI. Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia. J Clin Invest. 1994;93: 1677-1682.
24. Boyle PJ, Schwartz NS, Shah SD, Clutter WE, Cryer PE. Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and nondiabetics. N Engl J Med. 1988;318:1487-1492.
25. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-268.
26. Gerieh J, Davis J, Lorenzi M, et al. Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol. 1979;236:E380-E385.
27. Riddle MC, McDaniel PA, Tive LA. Glipizide GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM. Diabetes Care. 1997;20:992-994.
28. Santiago JV, White NH, Skor DA, Levandoski LA, Bier DM, Cryer PE. Defective glucose counterregulation limits intensive therapy of diabetes mellitus. Am J Physiol. 1984;247:E215-E220.